Grifols

GRIFOLS’ RED-FACED SHAREHOLDERS FINALLY SEE SOME GREENER PASTURES (BUY; 34% UPSIDE)

19/01/23 -" Amidst the volatile markets of the past two years, while Big Pharmas have materially outperformed – thereby regaining their safe-haven status - Smaller Pharmas have been out of favour due to both ..."

PDF page sample
Pages
55
Language
English
Published on
19/01/23
Download
You may also be interested by these reports :
02/02/23
Q4 sales met expectations, with both Pharmaceuticals and Diagnostics witnessing healthy growth, excluding receding COVID-19 testing tailwinds. In ...
02/02/23
Appreciating aprocitentan – How the royalty deal might look like – TP raised to CHF 18.20 (from 15.90) / Add reiterated
02/02/23
Novartis’ Q4 sales fell short of street expectations, although profitability improvements were noteworthy. The strong performances in Oncology and ...
31/01/23
We have integrated the first set of the 2022 figures. The significantly higher EPS stems mainly from the cancellation of the anticipated CHF-900m ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO